MESO - Mesoblast Ltd
Mesoblast Ltd Logo

MESO - Mesoblast Ltd

https://www.mesoblast.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.

52W High
$22.00
52W Low
$6.00
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.17
Valuation
Rich
As of 2024-12-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
454.55
EV/EBITDA (<8 favorable)
-6.55
EV/Revenue (<3 favorable)
101.08
P/S (TTM) (<3 favorable)
107.20
P/B (<3 favorable)
3.09
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.06%
Institutions (25–75% balanced)
2.69%
Shares Outstanding
128,117,000
Float
787,744,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2024-12-31 (Overview)
Revenue (TTM)
17,198,000
Gross Profit (TTM)
-22,739,000
EPS (TTM)
-0.85
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-3.02%
ROE (TTM) (>15% strong)
-0.19%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
4.59
Momentum
Bearish momentum
Value
0.0393
Previous
0.0441
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025